Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal

June 30, 2026

A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell engager (TCE) for autoimmune disorders in a potential $1.62 billion deal.

BioWorld BioWorld Science BioWorld Asia Deals and M&A Artificial intelligence Immune Antibody Protein Asia-Pacific U.S.

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement

BioWorld Science

Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...

Investors bet on transformative BCI tech for neuro disorders

BioWorld

An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....